Medifast Director Acquires 20,600 Shares Through Compensation and RSU Grant
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Medifast Director Jeffrey J. Brown reported significant stock acquisitions on June 25, 2025, through multiple transactions:
- Received 11,167.542 restricted stock units under the Director's Deferred Compensation Plan, which will fully vest on June 25, 2026
- Acquired 9,449.458 shares of common stock at $13.39 per share in lieu of cash compensation for director services
Following these transactions, Brown's total beneficial ownership includes:
- 38,577.647 shares held directly
- 4,232.967 shares held indirectly through the Jeffrey Brown Living Trust
The stock price was calculated using the 20-day moving average as of June 6, 2025. This Form 4 filing demonstrates significant insider accumulation of shares through compensation arrangements, suggesting continued alignment with shareholder interests.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 11,167.542 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 9,449.458 | $13.39 | $127K |
| holding | Common Stock | -- | -- | -- |
Footnotes (4)
- F1. These restricted stock units were granted under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated (the "Plan"), in connection with the payment of the reporting person's annual director fees. Each unit represents the right to receive one share of the Issuer's common stock. These shares are granted from the Issuer's Amended and Restated 2012 Share Incentive Plan and will vest in full on June 25, 2026.
- F2. The reporting person elected, pursuant to the Plan, to receive shares of the Issuer's common stock in lieu of cash compensation of annual service as a non-employee director of the Issuer.
- F3. The price per share of $13.39 is based on the 20-day moving average stock price of the Issuer's common stock as of June 6, 2025.
- F4. These shares are directly owned by Jeffrey Brown Living Trust, for which the reporting person is the sole trustee and sole beneficiary.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the vesting schedule for MED's restricted stock units granted to Jeffrey Brown?
What positions does Jeffrey Brown hold at MED according to the Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.